Search clinical trials for: WO 5001

Total 2196 results

n-Lorem Foundation
Mayo Clinic

Active, not recruiting

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Amyotrophic Lateral Sclerosis

United States
OXOLIFE

Completed

Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes. (OXOART2)

Infertility | Infertility, Female

Czechia, Spain, Poland
Red Queen Therapeutics, Inc.
PPD

Completed

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

COVID-19 | Infectious Disease | SARS CoV 2 Infection | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Regeneron Pharmaceuticals

Available

Compassionate Use of Vidutolimod
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

China
Equilibre Biopharmaceuticals B.V.

Active, not recruiting

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

Epilepsy

United States, Israel
Sarkana Pharma Inc

Terminated

A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants

Healthy Participants

Netherlands
Neurotech Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

Macular Telangiectasia Type 2

United States, Australia, Germany
Neurotech Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Macular Telangiectasia Type 2

United States, United Kingdom, Australia, France
Yaqrit Ltd
Assistance Publique - Hôpitaux de Paris; IRCCS Azienda Ospedaliero-Universitaria... and other collaborators

Withdrawn

Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis

Non-Alcoholic Steatohepatitis

France, Italy, Portugal, Spain, Switzerland, United Kingdom
Bioventus LLC

Active, not recruiting

Safety Study of PTP-001 for Treating Knee Osteoarthritis

Knee Osteoarthritis

United States
Pfizer

Completed

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Scar Prevention

United States
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Scar Prevention

United States
Vasomune Therapeutics, Inc.

Completed

A First-in-Human Study of AV-001 in Healthy Subjects

Covid19 | ARDS | Covid19-associated ARDS

United States
Balance Therapeutics

Completed

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

Idiopathic Hypersomnia | Narcolepsy Without Cataplexy

United States
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308

Diabetes Mellitus, Type II

Korea, Republic of
Balance Therapeutics

Completed

A Study to Investigate the Mass Balance of BTD-001 (HV103)

Molecular Mechanisms of Pharmacological Action

United Kingdom
Chong Kun Dang Pharmaceutical

Completed

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

Liver Dysfunction

Korea, Republic of
Baylor Research Institute

Completed

Transcutaneous Carbon Dioxide Monitoring Post Cardiac Surgery: Incidence and Severity Resp Insufficiency

Respiratory Insufficiency

United States
Xenon Pharmaceuticals Inc.

Completed

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Dental Pain

United States
Abbott

Completed

A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency

Exocrine Pancreatic Insufficiency, Chronic Pancreatitis

Japan
Chong Kun Dang Pharmaceutical

Completed

The Effect of Food on the Pharmacokinetic Characteristics of CKD-501 (CKD-501 FDI)

Healthy
University of Castilla-La Mancha
Ministry of science and innovation of Spain

Recruiting

HFAC Stimulation (30-50 Kilohertz) in Healthy Volunteers (High Frequency Alternating Current Stimulation) (HFA)

Pain | Healthy | Nerve Block

Spain
Northwell Health

Withdrawn

Mild Hypothermia for COVID-19 ARDS

COVID19 ARDS

United States
PharmAbcine

Completed

Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

Recurrent Glioblastoma
Horizon Pharma USA, Inc.

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Thyroid-Associated Ophthalmopathy | Thyroid Associated Ophthalmopathies

United Kingdom, United States, Germany, Italy
Latigo Biotherapeutics

Recruiting

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Healthy

New Zealand
MedRegen LLC

Recruiting

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

Wound of Skin | Abdominal Wound

United States
MedRegen LLC
Johns Hopkins University; ICON plc

Recruiting

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

COVID-19 | ARDS, Human | Regeneration | Stem Cells

United States
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Beijing Defengrui Biotechnology Co. Ltd

Terminated

A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients

COVID-19

China
Nacuity Pharmaceuticals, Inc.
Foundation Fighting Blindness

Active, not recruiting

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (SLO RP)

Usher Syndromes

Australia
Alumis Inc

Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Czechia
Anebulo Pharmaceuticals

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

Acute Cannabinoid Intoxication

Netherlands
Bloom Science

Completed

A Phase Ia Safety and Tolerability Study of BL-001

Healthy Volunteers

Switzerland
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Netherlands, United Kingdom, Czechia, Portugal, Hungary
Decathlon SE
EFOR, France

Terminated

Assessment of the Safety and Performance of Ankle Ligament Supports in the Context of a Return to Sport After Sprain

Ankle Sprain 1St Degree | Ankle Sprain 2Nd Degree | Ankle Sprain 3Rd Degree

France
Ossium Health, Inc.

Withdrawn

Mesenchymal Stem Cells (MSCs) for Perianal Fistula

Rectal Fistula
Cure Rare Disease, Inc
University of Massachusetts, Worcester

Active, not recruiting

Treatment of a Single Patient With CRD-TMH-001

Duchenne Muscular Dystrophy

United States
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Scar Prevention

United States
Novo Nordisk A/S

Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

Anemia

United States
Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Czechia, Portugal, Hungary, Germany, Poland
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan, Korea, Republic of, Japan
IMBiotechnologies Ltd.

Completed

OCL 500 Treatment of Women With Symptomatic Uterine Fibroids

Myoma | Uterine Fibroid | Leiomyoma

Canada
Olympus Corporation

Terminated

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

Emphysema

Japan
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
Xenon Pharmaceuticals Inc.

Completed

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Inherited Erythromelalgia | Primary Erythromelalgia

Netherlands
Neurotech Pharmaceuticals
The Emmes Company, LLC; The Lowy Medical Research Institute Limited

Completed

A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

Macular Telangiectasia Type 2

United States, Australia
Viridian Therapeutics, Inc.

Recruiting

A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Thyroid Eye Disease

United States
Biokuris s.a.

Recruiting

A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

Belgium
Entos Pharmaceuticals Inc.
Canadian Institutes of Health Research (CIHR); Aegis Life, Inc.; Clinical Pharma... and other collaborators

Completed

A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults

SARS-CoV-2

Burkina Faso, Canada, Senegal, South Africa

Search clinical trials for: WO 5001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations